HUMACYTE INC. - COMMON STOCK

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

28 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

26 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

25 Mar 2025 20:35:18 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

25 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

10 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

03 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

27 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

27 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

26 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

28 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

21 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

13 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

19 Dec 2024 22:47:10 By Nasdaq GlobeNewswire

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

02 Dec 2024 09:05:30 By Nasdaq GlobeNewswire

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

22 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

21 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

18 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

14 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte Third Quarter 2024 Financial Results and Business Update

08 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire